By Lila Rouland | Published on July 23, 2025 | 3 min read
#Cancer
#Adipocytes #TumorMetabolism #InnovativeTherapy
Cancer
cells thrive in a microenvironment that is poor in oxygen and nutrients. To
survive, they reprogram their metabolism to more efficiently absorb glucose
(aerobic glycolysis, or the Warburg effect) and fatty acids (fatty acid
oxidation, or FAO), enabling rapid proliferation.
In a
groundbreaking strategy, researchers propose the transplantation of engineered
adipose tissue (Adipose Manipulated Tissue, or AMT) to create “metabolic
competition” within the tumor microenvironment. The goal? Force adipocytes to
consume glucose and lipids so rapidly that the tumor can no longer access them.
The results, published in Nature Biotechnology, are striking.
Turning
adipocytes into energy burners
In this
study, human adipocytes were genetically reprogrammed using CRISPRa technology
to activate key genes of brown fat (UCP1, PRDM16, PPARGC1A), known for its high
energy expenditure.
The result?
These cells demonstrated a dramatic increase in oxygen, glucose, and fatty acid
consumption—essentially switching into “turbo” metabolic mode. When injected
near tumors in mice, the effect was radical: reduced tumor growth, lower
glucose uptake, decreased blood vessel formation, and even signs of apoptosis.
In vitro:
tumor cell proliferation drops sharply
Initially,
these “brown-like” adipocytes were co-cultured with five human cancer cell
lines (breast, colon, pancreas, prostate). Within three days:
- A 3- to 5-fold reduction in
tumor cell count.
- A decrease in MKI67 expression,
a marker of proliferation.
- A drop in glycolysis (ECAR,
GLUT4, GCK) and FAO (OCR, CD36, CPT1B).
CRISPRa
adipocytes, especially those expressing UCP1, outperformed conventional
metabolic treatments such as 6-aminonicotinamide (glycolysis inhibitor) and
etomoxir (FAO inhibitor).
In vivo:
tumors shrunk by half
In mice,
the implantation of modified adipose organoids adjacent to tumor xenografts led
to a >50% reduction in tumor volume within 3 weeks. Treated tumors
showed:
- Lower levels of hypoxia (CA9),
- Reduced
angiogenesis (CD31),
- Increased caspase-3, a marker
of apoptosis.
Analyses
also showed a global depletion of glucose and lipids in tumors, as if the
cancer cells could no longer feed themselves.
A
mechanism based on nutrient competition
The
UCP1-CRISPRa adipose organoids displayed:
- High intracellular levels of
glucose and fatty acids,
- While the associated tumors
were depleted of glucose and glycolytic metabolites (G6P, F6P, etc.).
When the
mice were fed high-fat or high-sugar diets, the anti-tumor effect of CRISPRa
adipocytes disappeared—confirming the crucial role of nutrient competition.
Transcriptomic
(RNA-seq) analysis of tumors treated with CRISPRa adipocytes (under a normal
diet) revealed:
- 7,102
differentially expressed genes, including:
- 6,623 downregulated (e.g., MKI67,
FASN, SCD, CPT1B),
- 479 upregulated (e.g., HOXD10,
GAS7),
- Suppressed pathways related to
cell growth, FAO, and cell division,
- Activated pathways linked to
apoptosis and cellular stress.
The effect was systemic and profound.
Effective
in Genetic Cancer Models Too
The
findings were validated in two established murine cancer models:
- The KPC pancreatic cancer
model,
- The MMTV-PyMT breast cancer
model.
In both,
CRISPRa adipose organoid implantation reduced tumor mass—regardless of implant
location—with sustained effects and no weight loss or toxicity.
What
about humans? Promising results with breast tissue
The
researchers went a step further by using human adipocytes isolated from breast
tissue. These were reprogrammed with UCP1-CRISPRa and co-cultured with
patient-derived tumor organoids (triple-negative and HR+ breast cancers).
Results:
- Significant reduction in tumor
organoid size and number,
- Decreased expression of MKI67,
GLUT4, GCK, CD36, and CPT1B,
- Effects observed across five
distinct clinical samples.
A new
metabolic weapon against cancer
This study
shows that genetically modified human adipocytes can slow tumor progression by
depriving cancer cells of essential nutrients. The approach:
- Can be personalized (e.g., UPP1
activation to target uridine-dependent cancers),
- Uses autologous cells (from the
patient),
- Is potentially reversible and
remotely controllable (via tetracycline or biomaterial platforms).
Future work
aims to validate this approach in humans and explore its application in other
cancer types and metabolic targets.
Read next: Lipids and breast cancer: metabolic reprogramming as a therapeutic target
About the Author – Lila Rouland
Doctor of Oncology, specialized in Biotechnology and Marketing
With dual expertise in science and marketing, Lila brings her knowledge to the service of healthcare innovation. After five years in international academic research, she transitioned into medical and scientific communication within the pharmaceutical industry. Now working as a medical writer and content developer, she is committed to highlighting scientific knowledge and conveying it to healthcare professionals with clarity and relevance. 
